{"id":"W2474545869","doi":"10.1182/blood.v106.11.446.446","title":"A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pharmacokinetics; Apoptosis; Pharmacology; Adverse effect; Chronic lymphocytic leukemia; Pharmacodynamics; Medicine; In vivo; Cmax; Bcl-2 family; Internal medicine; Immunology; Leukemia; Programmed cell death; Chemistry; Biology; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000407426,0.000565059,0.0009750765,0.0002592142,0.0001528045,0.00006527159,0.0006828763,0.0003067858,0.00006408281],"category_scores_gemma":[0.0003868122,0.0003820125,0.00031035,0.0008884801,0.0002799882,0.0001160754,0.000299553,0.0004016788,0.0001228319],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.03396529,"about_ca_system_score_gemma":0.03962838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001404183,"about_ca_topic_score_gemma":0.0005529079,"domain_scores_codex":[0.9953781,0.0002355961,0.001039554,0.0008499666,0.001391946,0.001104835],"domain_scores_gemma":[0.9968984,0.0001943927,0.0003575696,0.001579085,0.0004155404,0.0005550308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5676528,0.07340236,0.003350062,0.005528906,0.007488975,0.002056246,0.01178567,0.0008401213,0.1582234,0.00009592612,0.009715263,0.1598603],"study_design_scores_gemma":[0.8687474,0.0217774,0.001189971,0.001242391,0.001249322,0.0001740523,0.0000828242,0.001599036,0.1012249,0.000003696017,0.002117398,0.0005915602],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923391,0.000594338,0.00002413381,0.0001212119,0.0001679613,0.00544392,0.00007553495,0.0001297022,0.001104041],"genre_scores_gemma":[0.996506,0.0000661018,0.0002930929,0.0004416484,0.0007682686,0.0003444762,0.00008113684,0.0001401636,0.00135912],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3010947,"threshold_uncertainty_score":0.9998632,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01670014330814229,"score_gpt":0.2672895160565252,"score_spread":0.2505893727483829,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}